4142:TPE
Adimmune Corp
NT$15.85
arrow_downward
-1.86%(-0.30) 1 日
11月19日, 13:30:08 GMT+8 · TWD
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_auto4142 の上位の分析情報を生成しています...
始値
NT$16.20
高値
NT$16.25
安値
NT$15.70
時価総額
68.08億
平均出来高
109.29万
取引量
160.31万
株価収益率
91.85
52 週高値
NT$21.50
52 週安値
NT$15.65
EPS
NT$0.17
発行済株式数
2.35億
従業員数
564
始値
NT$16.20
高値
NT$16.25
安値
NT$15.70
時価総額
68.08億
平均出来高
109.29万
取引量
160.31万
株価収益率
91.85
52 週高値
NT$21.50
52 週安値
NT$15.65
EPS
NT$0.17
発行済株式数
2.35億
従業員数
564
ニュース記事
情報源: ウェブソース、ニュース パートナー
BigGo Finance
·
42 分前
UBS Sets S&P 500 Target of 8,200 by End-2027, Implying Roughly 12% Upside, But Cuts Rating to Neutral
Stocktwits
·
1 時間前
Nasdaq, Dow, S&P 500 Futures Climb Ahead Of Anthropic’s Record Debut: SLS, GLD, TTWO, UNH In Focus
Traders Union
·
3 時間前
S&P 500 dips below 200-day average after long streak, Ryan Detrick notes
プロフィール
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Adimmune Corp について